• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Respiratory Depression - Pipeline Review, H1 2012 Product Image

Respiratory Depression - Pipeline Review, H1 2012

  • ID: 2092657
  • March 2012
  • 36 pages
  • Global Markets Direct

Respiratory Depression – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Respiratory Depression - Pipeline Review, H1 2012', provides an overview of the Respiratory Depression therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Depression. 'Respiratory Depression - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Respiratory Depression.
- A review of the Respiratory Depression products under development by READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Respiratory Depression Overview
Therapeutics Development
An Overview of Pipeline Products for Respiratory Depression
Respiratory Depression Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Respiratory Depression Therapeutics – Products under Development by Companies
Companies Involved in Respiratory Depression Therapeutics Development
Cortex Pharmaceuticals, Inc.
Sihuan Pharmaceutical Holdings Group Ltd.
Respiratory Depression – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CX1942 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CX717 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nalmefene Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Respiratory Depression Therapeutics – Drug Profile Updates
Respiratory Depression Therapeutics – Discontinued Products
Respiratory Depression Therapeutics - Dormant Products
Respiratory Depression – Product Development Milestones
Featured News & Press Releases
Aug 24, 2011: Cortex Receives US Patent For Use Of Ampakine Molecules To Treat Respiratory Depression
Nov 04, 2009: Aeolus Pharmaceuticals’ AEOL 10150 Protects Lungs Against Chlorine Gas Exposure In Animal Studies
Sep 30, 2009: Discovery Labs And FDA Establish Path For Potential Surfaxin Approval
Sep 10, 2009: Discovery Labs And FDA Meet To Discuss Potential Path For Surfaxin Approval
May 11, 2009: Discovery Labs Meets FDA On To Discuss Surfaxin Complete Response Letter
May 04, 2009: Discovery Labs’ Kl4 Surfactant Shows Physiologic And Survival Benefit In A Preclinical Model For Severe Respiratory Condition
Apr 20, 2009: Discovery Labs Receives Complete Response From FDA For Surfaxin For Prevention Of RDS
Jan 05, 2009: Discovery Labs’ Surfaxin Phase 2 BPD Clinical Trial Results Published In Pediatrics
Nov 07, 2008: FDA Establishes Target Action Date Of April 17, 2009 For Potential Approval Of Discovery Labs’ Surfaxin
Nov 04, 2008: Discovery Labs Reports That It Has Not Yet Received FDA Notification Regarding Complete Response
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Respiratory Depression, H1 2012
Products under Development for Respiratory Depression – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Cortex Pharmaceuticals, Inc., H1 2012
Sihuan Pharmaceutical Holdings Group Ltd., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Respiratory Depression Therapeutics – Drug Profile Updates
Respiratory Depression Therapeutics – Discontinued Products
Respiratory Depression Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Respiratory Depression, H1 2012
Products under Development for Respiratory Depression – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos